US 12,264,336 B2
Platform for generating safe cell therapeutics
Richard Klemke, La Jolla, CA (US); and Huawei Wang, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, La Jolla, CA (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,531.
Application 17/554,531 is a continuation of application No. 17/159,595, filed on Jan. 27, 2021, granted, now 11,248,213.
Application 17/159,595 is a continuation of application No. 16/902,420, filed on Jun. 16, 2020, granted, now 10,960,071, issued on Mar. 30, 2021.
Application 16/902,420 is a continuation of application No. 16/636,249, previously published as PCT/US2018/045686, filed on Aug. 7, 2018.
Claims priority of provisional application 62/542,133, filed on Aug. 7, 2017.
Prior Publication US 2022/0177847 A1, Jun. 9, 2022
Int. Cl. C12N 5/0775 (2010.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2015.01); A61K 35/28 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/215 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/85 (2006.01); C12N 15/88 (2006.01)
CPC C12N 5/0662 (2013.01) [A61K 9/0019 (2013.01); A61K 35/12 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 39/001102 (2018.08); A61K 39/215 (2013.01); A61P 35/00 (2018.01); C12N 5/0646 (2013.01); C12N 5/0667 (2013.01); C12N 5/10 (2013.01); C12N 15/85 (2013.01); C12N 15/88 (2013.01); A61K 39/00 (2013.01); A61K 2039/515 (2013.01); A61K 2039/545 (2013.01); C12N 2501/999 (2013.01); C12N 2510/00 (2013.01); C12N 2513/00 (2013.01)] 28 Claims
 
1. A method for treating cancer or a neoplasm in a subject, the method comprising:
administering to a subject a cell without a nucleus, wherein the cell without the nucleus comprises a virus, wherein the virus comprises an exogenous nucleic acid molecule comprising a sequence encoding a therapeutic agent for the treatment of the cancer or the neoplasm, wherein the cell without the nucleus delivers the virus to a cancer cell or a neoplasm cell in the subject, thereby treating the cancer or the neoplasm in the subject, wherein the cell without the nucleus is derived from a nucleated parent cell, and wherein the nucleated parent cell comprises a mesenchymal stromal cell.